通讯作者: 王颖, wangying2012@qq.com

DOI：10.12201/bmr.202512.00068

• 摘要：目的：观察针刺足三里（ST36）配伍中脘（CV12）、气海（CV6）、天枢（ST25）对乳腺癌化疗后骨髓抑制的疗效。方法：选取2025年3月—6月收治的38例术后化疗患者，采用自身前后对照设计。首次化疗周期为对照组，出现骨髓抑制时予人粒细胞刺激因子；第二周期为试验组，在对照组基础上加用针刺上述穴位，两周期间隔1周作为洗脱期。通过监测血常规及统计重组人粒细胞刺激因子（Recombinant Human Granulocyte Colony-Stimulating Factor, rhG-CSF）总用量评估疗效。结果：试验组在相应时间点的白细胞、中性粒细胞、红细胞、血红蛋白和血小板计数显著高于对照组（均P<0.05），且所需rhG-CSF总剂量显著减少（P<0.05）。结论：针刺足三里配伍中脘、气海、天枢可缓解化疗所致骨髓抑制，减少rhG-CSF依赖，促进血液学恢复，该方案安全实用，值得推广。

  关键词： 乳腺癌; 针灸; 化疗; 骨髓抑制

   

  Abstract: Objective:This study aimed to evaluate the efficacy of acupuncture at Zusanli (ST36) combined with Zhongwan (CV12), Qihai (CV6), and Tianshu (ST25) in alleviating myelosuppression following chemotherapy in breast cancer patients. Methods:Thirty-eight postoperative chemotherapy patients admitted between March and June 2025 were enrolled in a self-controlled trial. The first chemotherapy cycle served as the control group, where recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered upon myelosuppression. The second cycle constituted the experimental group, receiving acupuncture at the above points in addition to the control treatment, with a one-week washout period between cycles. Efficacy was assessed by monitoring blood counts and total rhG-CSF usage. Results: the experimental group had significantly higher counts of white blood cells, neutrophils, red blood cells, hemoglobin, and platelets at multiple time points (all P < 0.05), along with a significantly lower total rhG-CSF dose (P < 0.05). conclusion:Acupuncture at Zusanli combined with Zhongwan, Qihai, and Tianshu can mitigate chemotherapy-induced myelosuppression, reduce reliance on rhG-CSF, and promote hematological recovery. This safe and practical acupuncture regimen is worthy of broader application.

  Key words: Breast Cancer; Chemotherapy; Acupuncture; Myelosuppression

  提交时间：2025-12-24

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 鲍呈洋, 杨颖涛. HER2阴性乳腺癌新辅助化疗疗效的影响因素. 2025. doi: 10.12201/bmr.202511.00048

  郭晴晴. 胃肠恶性肿瘤化疗后骨髓抑制中西医研究进展. 2025. doi: 10.12201/bmr.202506.00008

  姚根武, 王彦伟, 郭琎祎, 李露露, 党文博, 宋爱琳. 单细胞测序技术在乳腺癌中的研究进展. 2024. doi: 10.12201/bmr.202407.00053

  阮旭凌, 刘琦, 郭志恒, 晏峻峰. 基于LDA和XGBoost算法的乳腺癌预测模型构建研究. 2022. doi: 10.12201/bmr.202106.00007

  董佳荣, 潘玉真. 中医药治疗胰腺癌患者化疗后骨髓抑制的研究进展. 2025. doi: 10.12201/bmr.202508.00014

  李苑, 钱琳, 杨义. 中药治疗乳腺癌用药规律研究—基于真实世界的数据挖掘. 2025. doi: 10.12201/bmr.202506.00022

  林小雷, 马光泛, 陈小珍, 周森. 艾司氯胺酮对乳腺癌患者术后精神状态的影响. 2024. doi: 10.12201/bmr.202412.00054

  思小霞, 赵青, 景江新. 超声影像组学在预测乳腺癌分子分型中的应用进展. 2024. doi: 10.12201/bmr.202410.00040

  思小霞, 赵青, 景江新. 超声影像组学在乳腺癌中的应用进展及现状. 2024. doi: 10.12201/bmr.202412.00053

  邹信哲, 黄婉维, 黄凯君, 江丽君. 乳腺癌患者重返工作现状及影响因素Meta分析. 2025. doi: 10.12201/bmr.202509.00042

• 序号	提交日期	编号	操作
  1	2025-11-05	10.12201/bmr.202512.00068V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论